haldur, Author at TBD Pharmatech

Project: Small-molecule Novel Drug Ingredients Lab (RE.5.04.23-0268) – 150L Jacketed Glass Reactor

TBD Pharmatech’s recent procurement of 150L Jacketed glass reactor with thermostat, as part of the “Small-molecule Novel Drug Ingredients Lab” project, will add new capabilities to our organic synthesis services. This acquisition, funded by Enterprise Estonia (EAS) significantly enhances our capacity to conduct controlled, large-volume chemical reactions. The reactor is specifically designed for synthesizing complex chemical compounds, handling sensitive reaction conditions, and scaling up new product formulations. It is particularly effective for temperature-sensitive syntheses and multi-step organic processes, making it a critical asset for pioneering research and specialized chemical manufacturing. This upgrade will expand TBD Pharmatech’s portfolio of specialized services,

TBD Pharmatech Production Building Cornerstone Event

TBD Pharmatech at European Life Science CEO Forum

TBD Pharmatech’s CEO, Dr. Andrus Tasa, will be attending the prestigious 17th Annual European Life Science CEO Forum in person on February 28-29 in Zurich, Switzerland! This forum is a prime opportunity for networking, knowledge exchange, and collaboration within the life sciences industry. If you’re attending the event, we encourage you to book an appointment with Andrus Tasa. We look forward to connecting with you and exploring potential partnerships, innovations, or simply exchange ideas and industry insights. Let’s make the most out of this invaluable opportunity for growth and advancement in the field of life sciences! Read more about the

TBD Pharmatech team accepted the chemistry industry science challenge

During the scientific competition organized by Rakett69 Teadusstuudio, and the teams of Wolf Group, Akzo Nobel, TBD Pharmatech, and Eesti Energia, prominent players in the Estonian chemical industry, engaged in friendly competition on January 18, 2024. The studio buzzed with innovative ideas and experiments, providing valuable hands-on engineering workshops for all participants. On this occasion, the teams had to build the highest possible tower out of newspaper, deliver the space capsule safely to the ground, and fly the paper rocket as far as possible. Above all, the event highlighted the inspiring and enjoyable nature of tackling new challenges collaboratively with

Project: Small-molecule Novel Drug Ingredients Lab (RE.5.04.23-0268) – 5 kg flash

GMP API Development Process at TBD

TBD attended CPHI Barcelona 2023

TBD Pharmatech was proud to be a part of CPhI Barcelona 24-26 October 2023. This year was the busiest CPhI yet and the atmosphere on the show floor was inspirational. Over 52,000 passionate professionals from around the world gathered at CPhI to connect with 1,800+ exhibitors, face-to-face at the heart of pharma. Our team Andrus Tasa, Anneli Lainela, Tõnis Tasa, Andi Kipper, Ain Uustare, Indrek Tammeaid and Mai Mitt were inspired to network with the community and showcase TBD Pharmatech’s high quality API development and manufacturing services for small molecules. We’re excited about the prospect of further collaboration and engagement

TBD at CPHI Barcelona 2023

🌟 TBD Pharmatech is excited to attend this year’s CPHI Barcelona 2023 on 24-26 Oct 2023. CPHI Barcelona brings together the key experts, innovators, and suppliers to showcase their state-of-the-art work.TBD Pharmatech is proud to be a part of this year’s group to showcase our EU-based API CDMO and GMP manufacturing services. Our 7 person delegation, including CEO Andrus Tasa, is eager to connect with peers and future partners, as well as explore all opportunities.Reach out and we’ll meet you at STAND 7B30, API zone.

Project: PharmaBoost – EstLat Alliance in Drug Development

Drug substance development for smoking cessation On September 1st, 2023, TBD Pharmatech started together with the Latvian Institute of Organic Synthesis a new project PharmaBoost – EstLat Alliance in Drug Development. The total project funding amounts 582.436,25 EUR, with a substantial 80% contribution coming from the Estonia-Latvia Programme 2021-2027. This partnership embarks on a journey dedicated to advancing pharmaceutical development within the Baltic States. The primary goal is to pioneer an economically and environmentally sustainable production technology of an active pharmaceutical ingredient (API) crucial for a vital smoking cessation medication. Furthermore, the project is promoting the pharmaceutical innovation in the

Co-authored scientific publication in “Pharmaceuticals” – TMTHSI in metal-free click chemistry

A study co-authored by TBD and published in “Pharmaceuticals” in August 2023 has detailed the properties and potential applications in metal-free click chemistry for a new compound, tetramethylthiocycloheptyne sulfoximine (TMTHSI). The research was a collaborative effort involving six institutions: Cristal Therapeutics and Maastricht University in The Netherlands, Utrecht University, TBD Pharmatech in Estonia, Lonza AG in Switzerland, and the University of Glasgow in the UK. The study focused on three main aspects of TMTHSI. First, it examined the compound’s scalability and found that it can be produced in quantities of up to 100 grams. Second, the research looked at the